

## Issue of Shares on Exercise of Options and Cleansing Notice

**PERTH, Australia, 25 June 2026:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix<sup>®</sup> AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally, advises of the issue on 25 June 2026 of 57,000 ordinary shares on the exercise of vested options.

An Appendix 2A seeking quotation of the shares will be lodged following this announcement.

Accompanying this announcement is a cleansing notice issued in respect of the issue of shares.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

### About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](https://www.linkedin.com/company/artrya)

For more information:

### Corporate Enquiries

**John Konstantopoulos**

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: [contact@artrya.com](mailto:contact@artrya.com)

### Investor & Media Enquiries

**David Allen or John Granger**

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: [investors@artrya.com](mailto:investors@artrya.com)

-

## **SECONDARY TRADING NOTICE – NOTIFICATION PURSUANT TO PARAGRAPH 708A(5)(E) OF THE CORPORATIONS ACT 2001**

**PERTH, Australia, 25 June 2026:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix<sup>®</sup> AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally, provides this notice in accordance with section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) in relation to an issue on 25 June 2026 of 57,000 fully paid ordinary shares by Artrya on the exercise of unlisted options.

1. The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
2. As at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and sections 674 and 674A of the Corporations Act.
3. As at the date of this notice, there is no information that is “excluded information” (as defined in section 708A(7) of the Corporations Act) which is required to be disclosed by the Company in accordance with Section 708A(8) of the Corporations Act.

**Artrya Limited**  
Mark Pitts  
Company Secretary

**- Ends -**

This ASX Announcement is authorised for release by the Board of Artrya Limited.

### **About Artrya**

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](https://www.linkedin.com/company/artrya)

For more information:

#### **Corporate Enquiries**

**John Konstantopoulos**  
Co-Founder and Chief Executive Officer  
Tel: +61 8 6478 7816  
Email: [contact@artrya.com](mailto:contact@artrya.com)

#### **Investor & Media Enquiries**

**David Allen or John Granger**  
Hawkesbury Partners  
Tel: +61 499 100 038 or +61 410 577 155  
Email: [investors@artrya.com](mailto:investors@artrya.com)